الفهرس 
Coronary No-ReflowOnly 14 pages are availabe for public view
 |  | from | 131 |  |  |
| | | from | 131 | | |
Abstract
BACKGROUND:
The efficacy of trimetazidine (TMZ) in chronic coronary syndrome has been well demonstrated but data regarding TMZ in managing acute myocardial infarction (AMI) remain unclear. So, in our study we aimed to evaluate the role of TMZ in prevention of coronary no-reflow in STEMI patients undergoing primary Percutaneous Coronary Intervention.
METHODS:
A Prospective observational open label case control study was conducted on 200 STEMI patients who underwent PPCI. They were subdivided to 2 groups: group I (control group): 100 patients who were not treated with TMZ. group II (TMZ group): 100 patients who were treated by trimetazidine before and after PPCI for 1 month. All patients were assessed clinically, angiographically, ECG, Full labs and baseline echocardiography and after 1 month.
RESULTS:
There was a trend towards lower Incidence of coronary no reflow in the TMZ group (13%) as compared to the control group (18%) however it did not reach statistical significance (P-value= 0.32). TMZ group showed highly significant resolution of ST segment elevation in ECG after 24 hours as compared to the control group (P value=0.002). The TMZ group also showed statistically significantly improvement of LV ejection fraction as compared to the control group at 1 month follow up echocardiography (P-value=0.012).
CONCLUSIONSː
Although TMZ showed no significant improvement in TIMI flow in STEMI patients who underwent PPCI, however it was associated with greater resolution of ST segment elevation on ECG and improvement of LV systolic function (EF% and GLS by speckle tracking) after 1 month.